TATA Health International Holdings reported a HK$0.29 million loss attributable to shareholders for the six months ended 30 June 2026, a sharp reversal from the HK$20.60 million profit recorded a year earlier. Revenue declined 4.4% year on year to HK$47.28 million, while gross profit contracted 26.67% to HK$30.97 million. Gross margin narrowed to 65.5% from 85.3%, reflecting a jump in cost-of-sales ratio to 34.5% of revenue (1H 2025: 14.7%).
The swing into loss was driven by a combination of weaker footwear demand in Hong Kong and Macau, higher material costs and a smaller disposal gain. One-off income from subsidiary disposals contributed HK$16.20 million, well below the HK$34.67 million booked in the prior-year period. Operating expenses were lowered—staff costs fell 28.75% to HK$19.63 million following workforce restructuring—yet this was insufficient to offset the margin erosion.
Footwear remained the core business, delivering HK$46.22 million in revenue, down 6.7% year on year, as reduced sales in Hong Kong and Macau outweighed a HK$3.00 million contribution from newly launched footwear-materials supply in Mainland China. The Group’s nascent artificial-intelligence segment generated HK$1.06 million in its debut half-year, primarily from industrial robotics trials. The healthcare segment remained dormant with no revenue.
Cash and bank balances declined to HK$10.43 million from HK$17.92 million at end-2025, reflecting working-capital outflows. The current ratio improved to 0.57 times (31 Dec 2025: 0.50 times) after short-term borrowings were fully repaid, leaving no long-term debt other than HK$0.86 million in lease liabilities. Average trade receivables days lengthened to 23.4 from 15.8, while inventory days shortened to 109.6 from 189.6.
Auditor HLB issued a disclaimer of opinion on the 2025 financial statements due to missing records at disposed subsidiaries; management expects full removal of the disclaimer in the 2027 accounts. Post-period, a HK$0.14 million winding-up petition was filed by a former independent director over unpaid fees; no winding-up order has been granted.
No interim dividend was declared. Management will focus on stabilising its footwear division, scaling the AI initiatives and exploring AI-enabled healthcare opportunities, while relying on a HK$50.00 million shareholder facility—of which HK$25.51 million remains undrawn—to support liquidity over the next 12 months.